We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 362% below its sector, cheaper than its peers on earnings.
Jiangsu Sihuan Bioengineering Co., Ltd. is a Chinese pharmaceutical company. Its product portfolio includes anti-cancer biotherapeutics such as Drewson, prescribed for renal cancer, malignant melanoma, and cancerous effusions in the chest and abdomen. Another significant oncology drug, Xinde Lusheng, targets a much wider spectrum of malignancies, including kidney, melanoma, lung, gastric, malignant lymphoma, breast, ovarian, bowel, bladder, head and neck tumors, and leukemia, in addition to cancerous pleural effusions. Beyond oncology, the company also produces Xin grain health, a recombinant human granulocyte colony stimulating factor (G-CSF) injection. Additionally, Tourbo, a recombinant human erythropoietin (EPO) injection, addresses anemia stemming from kidney dysfunction in both dialysis-dependent and non-dialysis patients. Established in 1992, Jiangsu Sihuan Bioengineering is headquartered in Jiangyin, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 000518.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
